Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone
Source: Streetwise Reports  (4/20/26)
MeiraGTx Holdings Plc (MGTX:NASDAQ) reports 3-year gene therapy results, secures US$100M funding, and advances late-stage pipeline, signaling major commercial potential. More >

Life Sciences Co. Reports Strong Survival Data
Source: Jason Kolbert  (10/13/25)
OS Therapies Inc.'s (OSTX:NYSEAMERICAN) trial results are for its new immunotherapy in fully resected pulmonary metastatic osteosarcoma, noted a D. Boral Capital report. More >

Pharma Announces Faster Approval Pathway for Neurodegenerative Disease
Source: Dr. Leland Gershell and Rohan Mathur  (10/9/25)
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases. More >

Therapeutics Company Advances Gene Therapy Breakthrough
Source: Mitchell Kapoor and Dr. Raghuram Selvaraju  (10/9/25)
In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval. More >

New Remission Data on MG Patients Compelling
Source: Mitchell Kapoor  (9/5/25)
Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report. More >

Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis  (7/14/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report. More >

Interim Data From TID Trial Are Positive
Source: Streetwise Reports  (5/15/25)
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit. More >

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis  (4/28/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report. More >

Regenerative Medicine Firm OK'd To Advance Trial in T1D
Source: Streetwise Reports  (4/3/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication. More >

Cell Pouch Co. Peer Aborts Program Using Like Device
Source: Dr. Douglas Loe  (4/3/25)
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report. More >

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative
Source: Streetwise Reports  (12/3/24)
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced." More >

Two Firms Aim To Create Functional Cure for Type 1 Diabetes
Source: Streetwise Reports  (11/22/24)
Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs. More >

New Blood Cancer Treatment Shows Continued Response
Source: Dr. David Nierengarten  (11/7/24)
The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report. More >

Regenerative Med Co. Granted Second Tissue License
Source: Dr. Jonathan Aschoff  (11/7/24)
With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report. More >

Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments
Source: Streetwise Reports  (10/28/24)
This Canadian life sciences firm is developing an implantable cell-containing pouch, shown in clinical trial data thus far to be safe, well-tolerated and effective. Learn why several analysts rate the company Buy. More >

Co's. Cell Pouch Performs Well in Study
Source: Dr. Douglas Loe  (9/16/24)
Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report. More >

Implanted Cell Device Reaches 5 Year Milestone
Source: Stefan Quenneville  (9/16/24)
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report. More >

Trial Data Help Position Cell Pouch for Commercial Success
Source: Dr. Joseph Pantginis  (9/16/24)
The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report. More >

Biopharma Co. Ceases Program to Optimize Resources
Source: Hartaj Singh  (5/16/23)
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report. More >

Co.'s New Cell Therapy Shows Positive Effects
Source: Emily Bodnar  (4/19/23)
Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report. More >

Follow-up Results From T2 Diabetes Trial Positive
Source: Dr. Jonathan Aschoff   (4/14/23)
One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report. More >

Biotech Improves Efficiency of Its New Immunotherapy
Source: Dr. Jonathan Aschoff  (3/22/23)
The enhancements the company made to its investigative therapy that uses a patient's own immune cells were independently validated, noted a ROTH research report. More >

Data on New Cell Therapy for LBCL Encouraging, Analyst Says
Source: Justin Zelin   (12/16/22)
The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report. More >

HSCT/Gene Therapy Co. Sees Many Positive Catalysts in Q422
Source: Yun Zhong  (8/15/22)
Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics. More >

Biopharma Co. Planning BLA for DMD Drug
Source: Yun Zhong, Ph.D.  (8/5/22)
Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares. More >